Episode 167 - December 19, 2025

December 19, 2025

58 min episode · 2 min read

Daphne Zohar,Bruce Booth,Eric Schmidt

Episode

58 min

Read time

2 min

AI-Generated Summary

Published Feb 12, 2026

Key Takeaways

✓Follow-On Market Dynamics: October-November 2025 saw nearly $9 billion in follow-on financings across two months, the largest activity in 18 months. However, December deals show weaker post-market performance with stocks selling off after announcements, indicating investor fatigue and desire to lock in 2025 gains before year-end rather than sustained momentum.
✓FDA Operational Crisis: FDA staffing dropped to 2016 levels with 4,000 employees (20% of agency) departed in 2025. DOGE fired the HR department with no new hires completed, only transfers. Training new staff typically requires one year hiring plus two to three years training, creating long-term review capacity constraints despite day-to-day operations continuing.
✓MFN Pricing Risk: White House plans to expand Most Favored Nation pricing deals beyond large pharma to blanket policy across all biotechs. While initial deals with major drugmakers lack enforcement teeth, applying these frameworks to small and midsize companies could create disproportionate harm compared to large pharma's ability to absorb legacy product pricing pressure.
✓IPO Window Mechanics: Companies committing to IPO face four to five month timelines including legal work, SEC comments, and accounting requirements. With market sentiment improving post-Labor Day, expect 10-15 companies to flip from confidential to public S-1 filings in January 2026, though quality concerns exist about recycled 2024-2025 candidates with existing syndicates rushing to market first.
✓M&A as Ecosystem Function: Biotech M&A totaled nearly $240 billion in announced or closed deals by November 2025. Unlike tech, biotech lacks private growth capital providers at scale, making acquisitions by cash-rich pharma with existing distribution infrastructure the natural progression for delivering drugs to patients rather than building redundant commercial capabilities in overcapacity markets.

What It Covers

Biotech Hangout's 2025 year-end review examines market recovery after years of underperformance, with XBI reaching 124. Discussion covers FDA staffing crisis with 4,000 employees lost, MFN pricing policy concerns, follow-on financing trends exceeding $9 billion in October-November, and predictions for 2026 IPO activity and continued M&A momentum.

Key Questions Answered

•Follow-On Market Dynamics: October-November 2025 saw nearly $9 billion in follow-on financings across two months, the largest activity in 18 months. However, December deals show weaker post-market performance with stocks selling off after announcements, indicating investor fatigue and desire to lock in 2025 gains before year-end rather than sustained momentum.
•FDA Operational Crisis: FDA staffing dropped to 2016 levels with 4,000 employees (20% of agency) departed in 2025. DOGE fired the HR department with no new hires completed, only transfers. Training new staff typically requires one year hiring plus two to three years training, creating long-term review capacity constraints despite day-to-day operations continuing.
•MFN Pricing Risk: White House plans to expand Most Favored Nation pricing deals beyond large pharma to blanket policy across all biotechs. While initial deals with major drugmakers lack enforcement teeth, applying these frameworks to small and midsize companies could create disproportionate harm compared to large pharma's ability to absorb legacy product pricing pressure.
•IPO Window Mechanics: Companies committing to IPO face four to five month timelines including legal work, SEC comments, and accounting requirements. With market sentiment improving post-Labor Day, expect 10-15 companies to flip from confidential to public S-1 filings in January 2026, though quality concerns exist about recycled 2024-2025 candidates with existing syndicates rushing to market first.
•M&A as Ecosystem Function: Biotech M&A totaled nearly $240 billion in announced or closed deals by November 2025. Unlike tech, biotech lacks private growth capital providers at scale, making acquisitions by cash-rich pharma with existing distribution infrastructure the natural progression for delivering drugs to patients rather than building redundant commercial capabilities in overcapacity markets.

Notable Moment

The discussion revealed that Amicus Therapeutics, founded by John Crowley to treat his children's Pompe disease, was acquired by BioMarin for $4.8 billion after going public in May 2007 at $15 per share and selling for $14.50—despite market cap growing 13-15x, illustrating massive dilution required to build rare disease companies over two decades.

Know someone who'd find this useful?